Eintrag weiter verarbeiten
Long-term treatment with olanzapine in hospital conditions: Prevalence and predictors of the metabolic syndrome
Gespeichert in:
| Zeitschriftentitel: | Srpski arhiv za celokupno lekarstvo |
|---|---|
| Personen und Körperschaften: | , , , , , , , |
| In: | Srpski arhiv za celokupno lekarstvo, 143, 2015, 11-12, S. 712-718 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
National Library of Serbia
|
| Schlagwörter: |
| author_facet |
Popovic, Irena Ravanic, Dragan Jankovic, Slobodan Milovanovic, Dragan Folic, Marko Stanojevic, Albina Nenadovic, Milutin Ilic, Milena Popovic, Irena Ravanic, Dragan Jankovic, Slobodan Milovanovic, Dragan Folic, Marko Stanojevic, Albina Nenadovic, Milutin Ilic, Milena |
|---|---|
| author |
Popovic, Irena Ravanic, Dragan Jankovic, Slobodan Milovanovic, Dragan Folic, Marko Stanojevic, Albina Nenadovic, Milutin Ilic, Milena |
| spellingShingle |
Popovic, Irena Ravanic, Dragan Jankovic, Slobodan Milovanovic, Dragan Folic, Marko Stanojevic, Albina Nenadovic, Milutin Ilic, Milena Srpski arhiv za celokupno lekarstvo Long-term treatment with olanzapine in hospital conditions: Prevalence and predictors of the metabolic syndrome General Medicine |
| author_sort |
popovic, irena |
| spelling |
Popovic, Irena Ravanic, Dragan Jankovic, Slobodan Milovanovic, Dragan Folic, Marko Stanojevic, Albina Nenadovic, Milutin Ilic, Milena 0370-8179 2406-0895 National Library of Serbia General Medicine http://dx.doi.org/10.2298/sarh1512712p <jats:p>Introduction. The risk of metabolic abnormalities is greatly increased in schizophrenic patients started on an atypical antipsychotic medication. Patients with psychiatric disorders exceed mortality ranges resulting from, among others, increased risk of cardiovascular events. Other factors contributing to the development of metabolic syndrome include prolonged duration of illness, increasing age, female sex and lifestyle factors. Objective. This cross-sectional study was taken up to assess the prevalence of the metabolic syndrome (MetS) in schizophrenic patients receiving olanzapine monotherapy for at least six months and to determine the most important risk factors associated with metabolic syndrome presence in these patients. Methods. A total of 93 long term hospitalized schizophrenic patients (71 men, 22 women), had a screening of the following: case-history data, psychiatric scales, anthropometric measures, blood (fasting glucose, lipid status, C-reactive protein - CRP) and urine samples (microalbuminuria). Results. Prevalence of MetS according to International Diabetes Federation criteria in our study was 34.4%. The multivariate analysis distinguished the following significant predictors of MetS presence (in order of appearance): data about diabetes mellitus in family history (p=0.002), body mass index >25 kg/m2 (p=0.002), hyperlipidemia in family history (p=0.008), and elevated CRP value (p=0.042). Conclusion. High rate of MetS in patients treated with olanzapine in this study exceeds MetS prevalence in general population. Among observed parameters, our study pointed to several ?high risk? predictors associated with MetS presence. Regular monitoring of cardiometabolic risk factors is highly recommended. Positive heredity distress mentioned above may direct a psychiatrist to prescribe some other drug than olanzapine in the long term treatment of schizophrenia.</jats:p> Long-term treatment with olanzapine in hospital conditions: Prevalence and predictors of the metabolic syndrome Srpski arhiv za celokupno lekarstvo |
| doi_str_mv |
10.2298/sarh1512712p |
| facet_avail |
Online Free |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMjI5OC9zYXJoMTUxMjcxMnA |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMjI5OC9zYXJoMTUxMjcxMnA |
| institution |
DE-D275 DE-Bn3 DE-Brt1 DE-D161 DE-Zwi2 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 |
| imprint |
National Library of Serbia, 2015 |
| imprint_str_mv |
National Library of Serbia, 2015 |
| issn |
0370-8179 2406-0895 |
| issn_str_mv |
0370-8179 2406-0895 |
| language |
English |
| mega_collection |
National Library of Serbia (CrossRef) |
| match_str |
popovic2015longtermtreatmentwitholanzapineinhospitalconditionsprevalenceandpredictorsofthemetabolicsyndrome |
| publishDateSort |
2015 |
| publisher |
National Library of Serbia |
| recordtype |
ai |
| record_format |
ai |
| series |
Srpski arhiv za celokupno lekarstvo |
| source_id |
49 |
| title |
Long-term treatment with olanzapine in hospital conditions: Prevalence and predictors of the metabolic syndrome |
| title_unstemmed |
Long-term treatment with olanzapine in hospital conditions: Prevalence and predictors of the metabolic syndrome |
| title_full |
Long-term treatment with olanzapine in hospital conditions: Prevalence and predictors of the metabolic syndrome |
| title_fullStr |
Long-term treatment with olanzapine in hospital conditions: Prevalence and predictors of the metabolic syndrome |
| title_full_unstemmed |
Long-term treatment with olanzapine in hospital conditions: Prevalence and predictors of the metabolic syndrome |
| title_short |
Long-term treatment with olanzapine in hospital conditions: Prevalence and predictors of the metabolic syndrome |
| title_sort |
long-term treatment with olanzapine in hospital conditions: prevalence and predictors of the metabolic syndrome |
| topic |
General Medicine |
| url |
http://dx.doi.org/10.2298/sarh1512712p |
| publishDate |
2015 |
| physical |
712-718 |
| description |
<jats:p>Introduction. The risk of metabolic abnormalities is greatly increased in
schizophrenic patients started on an atypical antipsychotic medication.
Patients with psychiatric disorders exceed mortality ranges resulting from,
among others, increased risk of cardiovascular events. Other factors
contributing to the development of metabolic syndrome include prolonged
duration of illness, increasing age, female sex and lifestyle factors.
Objective. This cross-sectional study was taken up to assess the prevalence
of the metabolic syndrome (MetS) in schizophrenic patients receiving
olanzapine monotherapy for at least six months and to determine the most
important risk factors associated with metabolic syndrome presence in these
patients. Methods. A total of 93 long term hospitalized schizophrenic
patients (71 men, 22 women), had a screening of the following: case-history
data, psychiatric scales, anthropometric measures, blood (fasting glucose,
lipid status, C-reactive protein - CRP) and urine samples (microalbuminuria).
Results. Prevalence of MetS according to International Diabetes Federation
criteria in our study was 34.4%. The multivariate analysis distinguished the
following significant predictors of MetS presence (in order of appearance):
data about diabetes mellitus in family history (p=0.002), body mass index >25
kg/m2 (p=0.002), hyperlipidemia in family history (p=0.008), and elevated CRP
value (p=0.042). Conclusion. High rate of MetS in patients treated with
olanzapine in this study exceeds MetS prevalence in general population. Among
observed parameters, our study pointed to several ?high risk? predictors
associated with MetS presence. Regular monitoring of cardiometabolic risk
factors is highly recommended. Positive heredity distress mentioned above may
direct a psychiatrist to prescribe some other drug than olanzapine in the
long term treatment of schizophrenia.</jats:p> |
| container_issue |
11-12 |
| container_start_page |
712 |
| container_title |
Srpski arhiv za celokupno lekarstvo |
| container_volume |
143 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792341823660752906 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T16:26:02.403Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Long-term+treatment+with+olanzapine+in+hospital+conditions%3A+Prevalence+and+predictors+of+the+metabolic+syndrome&rft.date=2015-01-01&genre=article&issn=2406-0895&volume=143&issue=11-12&spage=712&epage=718&pages=712-718&jtitle=Srpski+arhiv+za+celokupno+lekarstvo&atitle=Long-term+treatment+with+olanzapine+in+hospital+conditions%3A+Prevalence+and+predictors+of+the+metabolic+syndrome&aulast=Ilic&aufirst=Milena&rft_id=info%3Adoi%2F10.2298%2Fsarh1512712p&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792341823660752906 |
| author | Popovic, Irena, Ravanic, Dragan, Jankovic, Slobodan, Milovanovic, Dragan, Folic, Marko, Stanojevic, Albina, Nenadovic, Milutin, Ilic, Milena |
| author_facet | Popovic, Irena, Ravanic, Dragan, Jankovic, Slobodan, Milovanovic, Dragan, Folic, Marko, Stanojevic, Albina, Nenadovic, Milutin, Ilic, Milena, Popovic, Irena, Ravanic, Dragan, Jankovic, Slobodan, Milovanovic, Dragan, Folic, Marko, Stanojevic, Albina, Nenadovic, Milutin, Ilic, Milena |
| author_sort | popovic, irena |
| container_issue | 11-12 |
| container_start_page | 712 |
| container_title | Srpski arhiv za celokupno lekarstvo |
| container_volume | 143 |
| description | <jats:p>Introduction. The risk of metabolic abnormalities is greatly increased in schizophrenic patients started on an atypical antipsychotic medication. Patients with psychiatric disorders exceed mortality ranges resulting from, among others, increased risk of cardiovascular events. Other factors contributing to the development of metabolic syndrome include prolonged duration of illness, increasing age, female sex and lifestyle factors. Objective. This cross-sectional study was taken up to assess the prevalence of the metabolic syndrome (MetS) in schizophrenic patients receiving olanzapine monotherapy for at least six months and to determine the most important risk factors associated with metabolic syndrome presence in these patients. Methods. A total of 93 long term hospitalized schizophrenic patients (71 men, 22 women), had a screening of the following: case-history data, psychiatric scales, anthropometric measures, blood (fasting glucose, lipid status, C-reactive protein - CRP) and urine samples (microalbuminuria). Results. Prevalence of MetS according to International Diabetes Federation criteria in our study was 34.4%. The multivariate analysis distinguished the following significant predictors of MetS presence (in order of appearance): data about diabetes mellitus in family history (p=0.002), body mass index >25 kg/m2 (p=0.002), hyperlipidemia in family history (p=0.008), and elevated CRP value (p=0.042). Conclusion. High rate of MetS in patients treated with olanzapine in this study exceeds MetS prevalence in general population. Among observed parameters, our study pointed to several ?high risk? predictors associated with MetS presence. Regular monitoring of cardiometabolic risk factors is highly recommended. Positive heredity distress mentioned above may direct a psychiatrist to prescribe some other drug than olanzapine in the long term treatment of schizophrenia.</jats:p> |
| doi_str_mv | 10.2298/sarh1512712p |
| facet_avail | Online, Free |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMjI5OC9zYXJoMTUxMjcxMnA |
| imprint | National Library of Serbia, 2015 |
| imprint_str_mv | National Library of Serbia, 2015 |
| institution | DE-D275, DE-Bn3, DE-Brt1, DE-D161, DE-Zwi2, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229 |
| issn | 0370-8179, 2406-0895 |
| issn_str_mv | 0370-8179, 2406-0895 |
| language | English |
| last_indexed | 2024-03-01T16:26:02.403Z |
| match_str | popovic2015longtermtreatmentwitholanzapineinhospitalconditionsprevalenceandpredictorsofthemetabolicsyndrome |
| mega_collection | National Library of Serbia (CrossRef) |
| physical | 712-718 |
| publishDate | 2015 |
| publishDateSort | 2015 |
| publisher | National Library of Serbia |
| record_format | ai |
| recordtype | ai |
| series | Srpski arhiv za celokupno lekarstvo |
| source_id | 49 |
| spelling | Popovic, Irena Ravanic, Dragan Jankovic, Slobodan Milovanovic, Dragan Folic, Marko Stanojevic, Albina Nenadovic, Milutin Ilic, Milena 0370-8179 2406-0895 National Library of Serbia General Medicine http://dx.doi.org/10.2298/sarh1512712p <jats:p>Introduction. The risk of metabolic abnormalities is greatly increased in schizophrenic patients started on an atypical antipsychotic medication. Patients with psychiatric disorders exceed mortality ranges resulting from, among others, increased risk of cardiovascular events. Other factors contributing to the development of metabolic syndrome include prolonged duration of illness, increasing age, female sex and lifestyle factors. Objective. This cross-sectional study was taken up to assess the prevalence of the metabolic syndrome (MetS) in schizophrenic patients receiving olanzapine monotherapy for at least six months and to determine the most important risk factors associated with metabolic syndrome presence in these patients. Methods. A total of 93 long term hospitalized schizophrenic patients (71 men, 22 women), had a screening of the following: case-history data, psychiatric scales, anthropometric measures, blood (fasting glucose, lipid status, C-reactive protein - CRP) and urine samples (microalbuminuria). Results. Prevalence of MetS according to International Diabetes Federation criteria in our study was 34.4%. The multivariate analysis distinguished the following significant predictors of MetS presence (in order of appearance): data about diabetes mellitus in family history (p=0.002), body mass index >25 kg/m2 (p=0.002), hyperlipidemia in family history (p=0.008), and elevated CRP value (p=0.042). Conclusion. High rate of MetS in patients treated with olanzapine in this study exceeds MetS prevalence in general population. Among observed parameters, our study pointed to several ?high risk? predictors associated with MetS presence. Regular monitoring of cardiometabolic risk factors is highly recommended. Positive heredity distress mentioned above may direct a psychiatrist to prescribe some other drug than olanzapine in the long term treatment of schizophrenia.</jats:p> Long-term treatment with olanzapine in hospital conditions: Prevalence and predictors of the metabolic syndrome Srpski arhiv za celokupno lekarstvo |
| spellingShingle | Popovic, Irena, Ravanic, Dragan, Jankovic, Slobodan, Milovanovic, Dragan, Folic, Marko, Stanojevic, Albina, Nenadovic, Milutin, Ilic, Milena, Srpski arhiv za celokupno lekarstvo, Long-term treatment with olanzapine in hospital conditions: Prevalence and predictors of the metabolic syndrome, General Medicine |
| title | Long-term treatment with olanzapine in hospital conditions: Prevalence and predictors of the metabolic syndrome |
| title_full | Long-term treatment with olanzapine in hospital conditions: Prevalence and predictors of the metabolic syndrome |
| title_fullStr | Long-term treatment with olanzapine in hospital conditions: Prevalence and predictors of the metabolic syndrome |
| title_full_unstemmed | Long-term treatment with olanzapine in hospital conditions: Prevalence and predictors of the metabolic syndrome |
| title_short | Long-term treatment with olanzapine in hospital conditions: Prevalence and predictors of the metabolic syndrome |
| title_sort | long-term treatment with olanzapine in hospital conditions: prevalence and predictors of the metabolic syndrome |
| title_unstemmed | Long-term treatment with olanzapine in hospital conditions: Prevalence and predictors of the metabolic syndrome |
| topic | General Medicine |
| url | http://dx.doi.org/10.2298/sarh1512712p |